Sujay Kango - Sep 21, 2021 Form 4 Insider Report for ACCELERON PHARMA INC (XLRN)

Role
EVP, Chief Commercial Officer
Signature
/s/ Adam M. Veness, as attorney-in-fact for Sujay Kango
Stock symbol
XLRN
Transactions as of
Sep 21, 2021
Transactions value $
-$547,100
Form type
4
Date filed
9/22/2021, 05:56 PM
Previous filing
Jun 8, 2021
Next filing
Sep 27, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XLRN Common Stock Options Exercise $203K +5K +27.01% $40.61 23.5K Sep 21, 2021 Direct F1
transaction XLRN Common Stock Sale -$750K -5K -21.27% $150.03 18.5K Sep 21, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLRN Option to Purchase Common Stock Options Exercise $0 -5K -14.29% $0.00 30K Sep 21, 2021 Common Stock 5K $40.61 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.45 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The shares of common stock underlying this stock option award vested as to 25% of the shares on the first anniversary of February 12, 2018 and the remaining shares vest in equal quarterly installments over the following three years thereafter.